Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
536 Leser
Artikel bewerten:
(1)

Ascensia Diabetes Care and Quattro Folia Announce Technology Collaboration to Support More Effortless Insulin Management for Patients

BASEL, Switzerland and ESPOO, Finland, September 12, 2017 /PRNewswire/ --

Ascensia Diabetes Care and Quattro Folia today announced a technology partnership that connects the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) from Ascensia to Quattro Folia's Balansio Mobile app. By enabling the effortless transfer of highly accurate blood glucose values for insulin calculations, this collaboration aims to optimize insulin management for patients.

Under the terms of the agreement, the CONTOUR®NEXT ONE meter will connect via Bluetooth to the Balansio Mobile app and directly deliver highly accurate blood glucose readings into the insulin calculator. Balansio is currently available in Finland, Sweden and UK, and there are plans to launch in more countries soon. The integration between these two solutions has recently been completed and is now available for people with diabetes who use Balansio in these countries. As Balansio launches in other European countries, the integration between these systems will also be made available.

"We are delighted to partner with Quattro Folia and connect to their impressive and easy to use Balansio tool. Enabling people with diabetes who are using Balansio to have seamless access to remarkably accurate readings from the CONTOUR®NEXT ONE blood glucose monitoring system will help to support them in managing their insulin therapy. This partnership is another step towards integrated diabetes management. By connecting our system to their highly effective insulin calculator, we are further achieving our goal of simplifying and improving the lives of people with diabetes," explained Michael Kloss, CEO of Ascensia Diabetes Care.

"We are thrilled to be partnering with Ascensia to seamlessly connect our systems together to help individuals with diabetes take better care of themselves." said Harri Okkonen, CEO of Quattro Folia. He added, "There is a great need for effective bolus calculators, as we see that more than 50% of individuals with diabetes using multiple daily injection treatment do not know how to calculate their insulin dose correctly. Furthermore, Balansio helps patients by calculating daily A1c estimations. Continuous A1c trends give the individual and their healthcare professional timely feedback and can help the individual to understand how their current activities affect the balance of their long-term care."

Balansio is designed to make the life of people with diabetes easier. The key feature of the app is the bolus calculator that uses a highly sophisticated algorithm to determine the correct insulin dose. The bolus calculator helps the patient to determine the right dose of insulin by wirelessly receiving the glucose reading from the paired meter and asking users to input the carbohydrates they plan to eat. Balansio can also automatically collect activity data through the mobile platform, which helps the user to better understand how physical activity is impacting the daily variation of blood glucose levels.

Balansio is a CE marked medical device and the bolus calculator is a CE certified class 2b medical device. Balansio is available for download for both Android and iOS devices.

The CONTOUR®NEXT ONE system features a highly accurate easy-to-use blood glucose smart meter that links to a mobile device via Bluetooth® connectivity. The meter connects to the CONTOUR® DIABETES app, a mobile app that collects, stores and analyzes patient blood glucose measurements delivered to it by the meter. The CONTOUR®NEXT ONE BGMS received CE Mark approval in Europe in April 2016. The CONTOUR® DIABETES app will be available for download from the Apple App Store (iOS) and Google Play (Android).

Notes for Editors

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.

Home to the world renowned CONTOUR® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 33 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

About Quattrofolia and Balansio

Quattro Folia is a high-tech company focusing on value-based healthcare solutions founded in 2012. Quattro Folia develops and offers Balansio, a software solution and cloud service for individuals with diabetes and other chronic conditions. Balansio helps patients to take control of their condition with the support of healthcare professionals and augmented clinical intelligence.

Balansio is designed to transform current appointment driven care practices into patient need driven healthcare enabling doctors, nurses and other professionals to focus on those patients requiring attention at the moment. This is achieved by highly automated collection of patients' self-care data, applying advanced analytics and algorithms, which adapt individually. Patient data and the findings are visualized for both the patient and the professional. Balansio provides efficient and secure communication between the patient and the care team. Balansio ecosystem is open for big and small healthcare service providers to join and transfer their healthcare services into next generation time and place independent on-line services.

For further information, please visit Balansio website at: http://www.balansio.com.

Ascensia Diabetes Care. Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.

Balansio is a registered trademark of Quattro Folia Oy.

The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license.

Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Google Play is a trademark of Google Inc.

For more information, please contact:

Joseph Delahunty, VP, Global Head of Communications
Ascensia Diabetes Care
E-mail: joseph.delahunty@ascensia.com
Phone: +41-79-422-9286

Paulus Carpelan, VP Marketing and New Business Development
Quattro Folia Oy

E-mail: paulus.carpelan@quattrofolia.com
Phone: +358-50-486-7516

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.